base busi show traction solid reiter overweight
pleas consid vote institut
investor poll life scienc diagnost tool
invest summari reiter overweight rate pt
htgm share see posit readout either pdp program
nearest signific potenti catalyst share continu think htg
see strength underli product-bas busi htg report revenu
ahead factset consensu manag reiter
revenu expect mdpt slight
beat driven strong revenu htg base ruo profil busi newli
contribut molecular diagnost product busi still await result
pdp pdp expect read within next quarter two
think share attract valuat ultim see acceler
balanc continu commerci execut
strong base profil busi htg report product revenu
servic revenu ahead
estim go quarter collabor revenu
light expect difficult-to-predict payment relat pdp program
model small contribut htg molecular diagnost
product think anyth north upsid
 autoimmun assay develop upsid share autoimmun
diseas seen littl diagnost innov make diseas difficult
diagnos therefor difficult clinician treat htg develop
autoimmun gene express assay request one larg pharma
client assay base quarter htg extend
agreement cover assay compat includ
still await readout activ pdp program nearest catalyst
share data readout precis diagnost partnership
program expect readout go/no-go decis within next quarter
two determin htg pharma partner plan develop drug pair
htg custom assay companion diagnost note htg
early-stag biopharma contract may lead addit pdp line
slight step end due inact contract
estim chang slightli rais revenu estim
reflect increas base
busi along mdx contribut widen loss per
share estim
 valuat base pt ev/sal multipl
disclosur section may found page
base pt ev/sal multipl revenu estim
multipl high growth molecular diagnost peer smid cap space
htgm may year away profit htgm may requir access capit
build toward profit compani end cash invest
howev compani may need rais addit capit order fund busi failur
gener addit capit may prevent compani reach profit
cancer profil market competit cancer profil market grow rapid
pace vari busi model compet htgm htgm face competit
molecular platform compani includ agil ghdx
roch among other htgm also compet central clia lab
foundat medicin roch market leader direct
competitor larg compani signific financi resourc could make difficult
smaller compani like htgm compet smaller compani also fight
visibl busi may limit htg reli develop partnership
pipelin custom may may translat new development partnership
growth may difficult htgm forecast success given relianc third parti
compani success htgm unabl convert pipelin custom collabor
agreement compani may difficulti achiev profit
regulatori environ molecular profil still evolv medicin evolv
htgm develop platform enter collabor agreement guidelin
current regulatori framework chang regulatori environ
reimburs molecular profil panel approv process companion diagnost
htgm may find difficult compet current busi model
exhibit htgm comparison cantor estim
sourc compani document factset cantor fitzgerald estim
htg molecular diagnost million except per share current priorcurr priorp gener share may
base pt ev/sal multipl revenu estim
multipl high growth molecular diagnost peer smid cap space
htgm may year away profit htgm may requir access capit build toward
profit compani end cash invest howev compani
may need rais addit capit order fund busi failur gener addit capit
may prevent compani reach profit
cancer profil market competit cancer profil market grow rapid pace
vari busi model compet htgm htgm face competit molecular
platform compani includ agil ghdx roch
among other htgm also compet central clia lab foundat medicin
roch guardant health market leader direct competitor larg compani
signific financi resourc could make difficult smaller compani like htgm
compet smaller compani also fight share
visibl busi may limit htg reli develop partnership
pipelin custom may may translat new development partnership growth
may difficult htgm forecast success given relianc third parti compani
success htgm unabl convert pipelin custom collabor agreement
compani may difficulti achiev profit
regulatori environ molecular profil still evolv medicin evolv htgm
develop platform enter collabor agreement guidelin current regulatori
framework chang regulatori environ reimburs molecular profil
panel approv process companion diagnost htgm may find difficult compet
current busi model
million except per share data
product relat servic revenu
product revenu
interest expens incom
incom incom tax
compani document cantor fitzgerald research
htgm commerci stage compani develop market product servic base proprietari technolog facilit
routin use target molecular profil use small amount biolog sampl htgm focu clinic applic
primari custom includ biopharmaceut compani academ research center molecular test laboratori
price close may
